Get App

Zydus Lifesciences receives final USFDA approval for Pemetrexed a chemotherapy drug

Pemetrexed is used to treat certain types of cancers, such as lung cancer and mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.
  • Updated On May 26, 2022 at 03:29 PM IST
Read by: 100 Industry Professionals
Reader Image Read by 100 Industry Professionals
Ahmedabad: Zydus Lifesciences Ltd. has received final approval from the United States Food and Drug Administration (US FDA) to market Pemetrexed a chemotherapy drug that works by slowing or stopping the growth of cancer cells in the strengths of 100 mg vial, 500 mg vial, and 1000 mg vial single-dose vials (USRLD: Alimta).

Pemetrexed is used to treat certain types of cancers, such as lung cancer and mesothelioma. The drug will be manufactured at Zydus Hospira. As per IQVIA MAT March'22), Pemetrexed for injection has a market size of $ 1,236 mn.

The group now has 314 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
  • Published On May 26, 2022 at 03:07 PM IST
Be the first one to comment.
Comment Now

COMMENTS

Comment Now Read Comment (1)

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App